CVS EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
CVS's ev/ebitda is higher than 82% of the last 10 years.
EV/EBITDA History
CVS EV/EBITDA by year
Yearly range of CVS’s ev/ebitda from 2016 to 2026. Over the full period it ranged from 7.1 to 21.9, averaging 11.6.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 13.7 | 16.6 | 19.5 | 13.9 |
| 2025 | 9.5 | 12.2 | 18.9 | 18.9 |
| 2024 | 8.2 | 9.3 | 11.3 | 9.6 |
| 2023 | 8.3 | 12.5 | 15.6 | 9.2 |
| 2022 | 10.5 | 12.7 | 17.5 | 16.2 |
| 2021 | 9.8 | 10.7 | 12.0 | 11.7 |
| 2020 | 8.2 | 9.4 | 11.2 | 9.8 |
| 2019 | 11.0 | 16.4 | 21.9 | 11.0 |
| 2018 | 7.1 | 9.5 | 21.2 | 21.2 |
| 2017 | 7.8 | 8.8 | 9.4 | 8.3 |
| 2016 | 8.7 | 9.6 | 10.9 | 9.2 |
Get notified when CVS EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is CVS EV/EBITDA High or Low Right Now?
CVS Health Corporation's EV/EBITDA is currently 13.9, which is historically pricey relative to its 10-year historical range. The 10-year median EV/EBITDA for CVS is approximately 10.7. See all CVS valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.